Axsome Therapeutics, Inc. (AXSM) Earnings
Axsome Therapeutics, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Next earnings (estimated)
Around Feb 22, 2027
From past filing pattern
Get notified when AXSM reports →Last reported earnings
Nov 2, 2026
From the latest earnings 8-K
Revenue • FY2025
$638.5M
▲ 65.5%YoY
Diluted EPS • FY2025
-$3.68
▲ 38.6%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from AXSM's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $638.5M | -$183.17M | $591.02M | -$3.68 | -$93.89M | -26.1% | +65.5% |
| FY2024 | $385.69M | -$287.22M | $352.39M | -$5.99 | -$128.68M | -72.7% | +42.5% |
| FY2023 | $270.6M | -$239.24M | $244.53M | -$5.27 | -$145.66M | -85.7% | +440.8% |
| FY2022 | $50.04M | -$187.13M | $44.84M | -$4.60 | -$117.21M | -359.3% | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Nov 2, 2026 | 8-K (2.02) | 0001193125-26-442628EDGAR |
| Aug 10, 2026 | 8-K (2.02) | 0001193125-26-341206EDGAR |
| May 4, 2026 | 8-K (2.02) | 0001193125-26-202506EDGAR |
| Feb 23, 2026 | 8-K (2.02) | 0001193125-26-062421EDGAR |
| Jan 12, 2026 | 8-K (2.02) | 0001193125-26-009744EDGAR |
| Nov 3, 2025 | 8-K (2.02) | 0001193125-25-261651EDGAR |
| Aug 4, 2025 | 8-K (2.02) | 0000950170-25-101624EDGAR |
| May 5, 2025 | 8-K (2.02) | 0000950170-25-063158EDGAR |
Never miss a AXSM filing.
Get an email when AXSM files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 9, 2026Source: SEC EDGAR.